Overview

Individualized Obesity Pharmacotherapy

Status:
Active, not recruiting

Trial end date:
2022-07-01

Target enrollment:

Participant gender:

Summary

The researchers are trying to identify the specific characteristics (phenotypes) that may be useful to help select the right medication for weight loss.

Phase:

Phase 3

Details

Lead Sponsor:

Mayo Clinic

Treatments:

Bupropion
Liraglutide
Naltrexone
Phentermine
Topiramate